Ipamorelin 101: What It Is, How It Works & Why It's the Cleanest GHRP

Ipamorelin is the gold standard GHRP in research — it triggers clean GH pulses without the cortisol spike, appetite surge, or prolactin elevation that plague older growth hormone releasing peptides. This guide covers why that matters, how the mechanism works, and how researchers use it standalone and stacked.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (5 amino acids) that acts as a growth hormone secretagogue by mimicking ghrelin — the "hunger hormone" that also signals the pituitary to release growth hormone. It was developed by Novo Nordisk in the 1990s and reached Phase 2 clinical trials for postoperative ileus before commercial development was shelved.

It belongs to the GHRP (growth hormone releasing peptide) family, alongside GHRP-2 and GHRP-6. What distinguishes it is selectivity: ipamorelin stimulates GH release at the pituitary without triggering the off-target hormonal effects that make other GHRPs less desirable in research settings.

How It Works

Ipamorelin binds and activates the GHS-R1a receptor (growth hormone secretagogue receptor) in the pituitary gland and hypothalamus. This triggers a burst of GH release — mimicking the natural pulsatile GH secretion pattern rather than producing a continuous flat elevation.

Natural GH release happens in pulses, primarily during deep sleep. Ipamorelin amplifies these pulses without suppressing the feedback loop that governs natural GH regulation. This preserves the pituitary's own signaling architecture, which is a key reason it's favored in longer research protocols.

Ipamorelin vs Other GHRPs

The GHRP family includes several compounds. Here's how ipamorelin stacks up on selectivity — the key differentiating factor:

The clean cortisol and prolactin profile is why ipamorelin is the default GHRP choice in most modern research protocols. Elevated cortisol from GHRP-2/6 can partially offset anabolic GH effects and creates confounding variables in research. Ipamorelin eliminates that issue.

Dosing Protocol

Research protocols for ipamorelin typically mirror the body's natural GH pulse timing — fasted state, pre-sleep dosing produces the strongest response due to overlap with the natural nocturnal GH surge.

Stacking with CJC-1295

The CJC-1295 / Ipamorelin combination is one of the most studied GH peptide stacks in research. Understanding why it works so well requires knowing what each compound does:

• CJC-1295 — a GHRH analogue. It stimulates GHRH receptors in the pituitary, raising the baseline level of GH secretion over time. Think of it as raising the "floor" of GH output.
• Ipamorelin — a ghrelin receptor agonist. It produces acute GH pulses on top of whatever baseline exists. Think of it as amplifying the "spikes."

Together, you get sustained baseline elevation from CJC-1295 plus sharp pulsatile peaks from ipamorelin — through two completely different receptor pathways. The synergy is additive to superadditive depending on the study model used.

Side Effects

Ipamorelin has a notably clean side effect profile compared to other GHRPs. Most reported effects are mild and dose-dependent:

• Injection site reactions — mild redness/swelling; resolves quickly. Rotate sites to minimize.
• Transient flushing or tingling — reported by some subjects immediately post-injection; typically resolves within 30 minutes.
• Water retention — GH elevation increases sodium and water retention. Usually mild at research doses; more pronounced at higher doses.
• Fatigue/drowsiness — GH pulses naturally promote sleep onset. Pre-sleep dosing turns this into a feature rather than a side effect.
• Headache — occasionally reported; typically at higher doses or in early weeks of use.

Crucially: no significant cortisol elevation, no prolactin elevation, and no significant appetite stimulation have been observed at standard research doses — the key advantages over GHRP-2 and GHRP-6.

Research Sourcing